74MO HERIZON overall survival results: A study of IMU-131, a HER2 targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2 overexpressing metastatic or a... von Maglakelidze, M., Ryspayeva, D., Andric, Z.G., Petrovic, Z., Bulat, I.V., Nikolic, I.V., Chawla, T., Nagarkar, R., Wiedermann, U., Blumenstein, B.A., Chong, L.M.O., Ede, N.J., Nixon, B., Good, A.J.

Volltext

P1.15-08 Phase 1: IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy as Monotherapy or in Combination with Atezolizumab, in Adults with Non-Small Cell Lung Cancer von Richardson, G.E., Park, J.J., Boyer, M.J., Gutierrez, M., Carbone, D.P., Savvides, P., Kaumaya, P., Bekaii-Saab, T.S., Phan, T.G., Chong, L.M.O., Cha, S., Ede, N., Nixon, B., Withana, N.P., Good, A.J.

Volltext